| Vasculitis and related conditions | Lifetime | 7 | ES 1 | 99.85 |
| Systemic Lupus Erythematosus Research | Lifetime | 30 | ES 2 | 99.78 |
| Otitis Media and Relapsing Polychondritis | Lifetime | 4 | ES 1 | 99.83 |
| Coagulation, Bradykinin, Polyphosphates, and Angioedema | Lifetime | 36 | ES 1 | 99.35 |
| Urticaria and Related Conditions | Lifetime | 33 | ES 1 | 99.44 |
| Rheumatoid Arthritis Research and Therapies | Lifetime | 66 | ES 1 | 99.67 |
| Renal Diseases and Glomerulopathies | Lifetime | 70 | ES 5 | 99.47 |
| Atherosclerosis and Cardiovascular Diseases | Lifetime | 66 | ES 3 | 99.36 |
| Inflammasome and immune disorders | Lifetime | 73 | ES 1 | 98.91 |
| Autoimmune Bullous Skin Diseases | Lifetime | 101 | ES 2 | 98.90 |
| Cell Adhesion Molecules Research | Lifetime | 324 | ES 3 | 98.89 |
| Systemic Sclerosis and Related Diseases | Lifetime | 134 | ES 3 | 98.73 |
| Spondyloarthritis Studies and Treatments | Lifetime | 87 | ES 1 | 98.95 |
| Adipokines, Inflammation, and Metabolic Diseases | Lifetime | 401 | ES 20 | 98.21 |
| Autoimmune and Inflammatory Disorders Research | Lifetime | 293 | ES 8 | 98.11 |
| Sarcoidosis and Beryllium Toxicity Research | Lifetime | 185 | ES 4 | 97.20 |
| Cytokine Signaling Pathways and Interactions | Lifetime | 532 | ES 5 | 97.28 |
| Psoriasis: Treatment and Pathogenesis | Lifetime | 342 | ES 8 | 97.32 |
| Galectins and Cancer Biology | Lifetime | 501 | ES 5 | 95.43 |
| Eosinophilic Disorders and Syndromes | Lifetime | 575 | ES 13 | 96.05 |
| Myeloproliferative Neoplasms: Diagnosis and Treatment | Lifetime | 599 | ES 19 | 95.91 |
| Ocular Diseases and Behçet’s Syndrome | Lifetime | 613 | ES 18 | 95.80 |
| Autoimmune and Inflammatory Disorders | Lifetime | 375 | ES 17 | 94.74 |
| Infectious Diseases and Tuberculosis | Lifetime | 934 | ES 24 | 93.69 |
| Inflammatory Myopathies and Dermatomyositis | Lifetime | 448 | ES 12 | 94.29 |
| IgG4-Related and Inflammatory Diseases | Lifetime | 345 | ES 3 | 90.70 |
| Gout, Hyperuricemia, Uric Acid | Lifetime | 787 | ES 19 | 88.64 |
| Protein Tyrosine Phosphatases | Lifetime | 770 | ES 14 | 87.63 |
| Biomarkers in Disease Mechanisms | Lifetime | 621 | ES 10 | 84.53 |
| Skin Diseases and Diabetes | Lifetime | 524 | ES 26 | 87.40 |
| Dermatological and COVID-19 studies | Lifetime | 418 | ES 20 | 84.13 |
| Hidradenitis Suppurativa and Treatments | Lifetime | 483 | ES 26 | 79.46 |
| Inflammation biomarkers and pathways | Lifetime | 676 | ES 19 | 74.25 |
| Paraoxonase enzyme and polymorphisms | Lifetime | 910 | ES 65 | 63.83 |
| Systemic Lupus Erythematosus Research | 2021-2025 | 58 | ES 2 | 98.74 |
| Vasculitis and related conditions | 2021-2025 | 26 | ES 2 | 98.69 |
| Rheumatoid Arthritis Research and Therapies | 2021-2025 | 105 | ES 2 | 98.09 |
| Renal Diseases and Glomerulopathies | 2021-2025 | 148 | ES 6 | 96.86 |
| Otitis Media and Relapsing Polychondritis | 2021-2025 | 30 | ES 2 | 96.32 |
| Spondyloarthritis Studies and Treatments | 2021-2025 | 108 | ES 7 | 96.68 |
| Systemic Sclerosis and Related Diseases | 2021-2025 | 185 | ES 10 | 94.12 |
| Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis | 2021-2025 | 386 | ES 9 | 93.51 |
| Atherosclerosis and Cardiovascular Diseases | 2021-2025 | 176 | ES 4 | 91.81 |
| Coagulation, Bradykinin, Polyphosphates, and Angioedema | 2021-2025 | 230 | ES 9 | 90.43 |
| Sarcoidosis and Beryllium Toxicity Research | 2021-2025 | 233 | ES 10 | 89.09 |
| Adipokines, Inflammation, and Metabolic Diseases | 2021-2025 | 387 | ES 20 | 85.82 |
| Psoriasis: Treatment and Pathogenesis | 2021-2025 | 604 | ES 34 | 87.42 |
| Inflammatory Myopathies and Dermatomyositis | 2021-2025 | 331 | ES 10 | 85.56 |
| Cell Adhesion Molecules Research | 2021-2025 | 411 | ES 6 | 79.16 |
| Autoimmune and Inflammatory Disorders Research | 2021-2025 | 843 | ES 27 | 84.50 |
| Ocular Diseases and Behçet’s Syndrome | 2021-2025 | 575 | ES 11 | 82.90 |
| Complement system in diseases | 2021-2025 | 401 | ES 21 | 82.43 |
| Cytokine Signaling Pathways and Interactions | 2021-2025 | 439 | ES 6 | 76.99 |
| Urticaria and Related Conditions | 2021-2025 | 787 | ES 31 | 77.78 |
| IgG4-Related and Inflammatory Diseases | 2021-2025 | 211 | ES 5 | 72.57 |
| Lipid metabolism and disorders | 2021-2025 | 582 | ES 20 | 68.60 |
| Autoimmune and Inflammatory Disorders | 2021-2025 | 597 | ES 28 | 67.85 |
| Skin Diseases and Diabetes | 2021-2025 | 259 | ES 13 | 65.19 |
| Connective Tissue Growth Factor Research | 2021-2025 | 145 | ES 7 | 53.38 |
